3TR

UNIPI Team Leader: Prof. Marta Mosca, Dipartimento di Medicina Clinica e Sperimentale

The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression.

The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Coordinator
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, Spain

Participants

THE UNIVERSITY OF MANCHESTER, United Kingdom
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL, Germany
UNIVERSITY OF LEICESTER, United Kingdom
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH, Germany
FUNDACIO CENTRE DE REGULACIO GENOMICA, Spain
EUROPEAN RESPIRATORY SOCIETY, Switzerland
FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO, Italy
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, Netherlands
ACADEMISCH ZIEKENHUIS GRONINGEN, Netherlands
ALACRIS THERANOSTICS GMBH, Germany
ATRYS HEALTH, SA, Spain
AZIENDA OSPEDALIERA DI PADOVA, Italy
AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER, Italy
Universitair Ziekenhuis Gent, Belgium
REGION HOVEDSTADEN, Denmark
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY, France
UNIVERSITY OF GLASGOW, United Kingdom
CHARITE - UNIVERSITAETSMEDIZIN BERLIN, Germany
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS, Spain
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER, Spain
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P., Spain
Deutsches Rheuma-Forschungszentrum Berlin, Germany
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING, Belgium
EUROPEAN LUNG FOUNDATION, United Kingdom
GENOS DOO ZA VJESTACENJE I ANALIZU, Croatia
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE, United Kingdom
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, France
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES, Portugal
KAROLINSKA INSTITUTET, Sweden
LUPUS EUROPE, United Kingdom
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV, Germany
MEDIZINISCHE HOCHSCHULE HANNOVER, Germany
OREBRO UNIVERSITY, Sweden
OWLSTONE MEDICAL LIMITED, United Kingdom
PHILIPPS UNIVERSITAET MARBURG, Germany
QUEEN MARY UNIVERSITY OF LONDON, United Kingdom
SERVICIO ANDALUZ DE SALUD, Spain
SERVICIO MADRILENO DE SALUD, Spain
SIP SERVICE S.R.L., Italy
SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE, France
STICHTING VUMC, Netherlands
TECHNISCHE UNIVERSITAET DRESDEN, Germany
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE, United Kingdom
THE QUEEN'S UNIVERSITY OF BELFAST, United Kingdom
UNIVERSITA DEGLI STUDI DI CATANIA, Italy
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO, Italy
UNIVERSITA DEGLI STUDI DI CAGLIARI, Italy
UNIVERSITA DEGLI STUDI DI GENOVA, Italy
UNIVERSITA DI PISA, Italy
UNIVERSITAT BASEL, Switzerland
CLINIQUES UNIVERSITAIRES SAINT-LUC, Belgium
UNIVERSITE DE BRETAGNE OCCIDENTALE, France
UNIVERSITEIT HASSELT, Belgium
UNIVERSITETET I BERGEN, Norway
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN, Ireland
UNIVERSITY COLLEGE LONDON, United Kingdom
KATHOLIEKE UNIVERSITEIT LEUVEN, Belgium
UNIVERSITY OF SOUTHAMPTON, United Kingdom
UNIVERSYTET MEDYCZNY W LODZI., Poland
VIB VZW, Belgium
SANOFI-AVENTIS DEUTSCHLAND GMBH, Germany
JANSSEN PHARMACEUTICA NV, Belgium
TAKEDA DEVELOPMENT CENTRE EUROPE LTD., United Kingdom
ASTRAZENECA AB, Sweden
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD., United Kingdom
NOVARTIS PHARMA AG, Switzerland
PFIZER LIMITED, United Kingdom
F. HOFFMANN-LA ROCHE AG, Switzerland

Start date 1 September 2019
End date 31 August 2026
Project cost € € 80 803 177,75
Project funding € 40 273 191,50
Unipi quota € 292 500
Call title H2020-JTI-IMI2-2018-14-two-stage
Unipi role Participant
Project website https://3tr-imi.eu/